BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters2025-04-01
BUZZ-Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls; brokerage says cancer drug trial data underwhelms

** Shares of drug developer Compass Therapeutics CMPX.O fall 14.5% to $1.62

** CMPX says its experimental biliary tract cancer drug, tovecimig, when combined with chemotherapy, showed an overall response rate $(ORR.AU)$ of 17.1% in patients compared to 5.3% who received chemotherapy alone

** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined period of time

** Brokerage Leerink Partners says this response rate is lower than expected, and lower than what was seen in previous trials

** Other treatments, such as Enhertu by AstraZeneca AZN.L and Pemazyre by Incyte INCY.O, have shown higher response rates in similar patient populations, brokerage says

** Including sessions moves, CMPX stock up 31% YTD

(Reporting by Padmanabhan Ananthan)

((padmanabhan.ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment